Preclinical assets market
Preclinical Assets Market, by Service ( Bioanalysis and DMPK studies (In vitro, In-vivo), Toxicology Testing (GLP, Non-GLP), compound management (Process R&D, Custom Synthesis, Asymmetric Synthesis & Others (Scale-up, cGMP, etc.), Safety Pharmacology, Others(Chemistry, etc.)), by Model type (Patient Derived Organoid (PDO) Model, Patient derived xenograft model), by End user (Biopharmaceutical Companies, Government Institutes & Others (Academic and Research institutes) ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
- Nov 2022
- CMI5326
- 176 Pages
- Excel & Pdf
- Pharmaceutical
Preclinical assets is a fully integrated CRO (Clinical Research Organization) providing services to support drug discovery programs from target discovery through IND (Investigational New Drug) filing and managing Phase I-IV clinical trials. Preclinical resources, services for HTS (High-throughput screening) and assay development, synthetic organic and medicinal chemistry, DMPK/in-vivo pharmacology and safety pharmacology, toxicology, as well as clinical trial services for the regulatory approval of novel drug and medical device products.
Global preclinical assets market size is valued at US$ 5,250.2 million in 2022 and is expected to witness a CAGR of 7.5% over the forecast period (2022 – 2030).
Figure 1.Global Preclinical Assets Market Share (%), by Service, 2022
Global Preclinical Assets Market– Drivers
Increasing number of new test launch in the toxicology by the market players is expected to drive growth of the global preclinical assets market over the forecast period.
Increasing number of launch of new toxicology test by the key market players is expected to drive growth of the global preclinical assets market over the forecast period. For instance, in October 2018, SGS SA, a multinational company announced the launch of the in-vitro testing which consists of the development of present cell/tissue culture capabilities, flow cytometry, and mass spectrometry facilities, along with the introduction of high throughput screening, automation, and multiplexing technologies. The launch of this toxicology test will help the company to further strengthen and expand its product portfolio.
Preclinical Assets Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2021 | Market Size in 2022: | US$ 5,250.2 Mn |
Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
Forecast Period 2022 to 2030 CAGR: | 7.5% | 2030 Value Projection: | US$ 9,778.8 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Eurofins Scientific, ICON plc, WuXi AppTec, Viroclinics Xplore, Medpace, Inc., Charles River Laboratories., Pharmatest Services, PPD Inc., SGS SA (SGS), Intertek Group plc, Labcorp Drug Development, Laboratory Corporation of America, Inc., Crown Bioscience, Comparative Biosciences, Inc., TCG Lifesciences Private Limited., Shanghai Medicilon Inc., Domainex, Absorption Systems, AmplifyBio, and IQVIA |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Figure 2. Global Preclinical Assets Market Share (%), by Region, 2022
Increasing number of inorganic strategies such as acquisition by market players in North America is expected to drive growth of the global preclinical assets market over the forecast period.
Inorganic strategies such as acquisition by the key market players in North America are expected to drive growth of the global preclinical assets market over the forecast period. For instance, on May 9, 2022, Labcorp, a global life sciences company, and AtlantiCare, a health care organization in southern New Jersey, U.S., announced that they had closed a transaction to expand their long-term strategic relationship. Labcorp will acquire select assets from AtlantiCare’s clinical outreach business, which serves the AtlantiCare Physician Group and Affiliated Physicians and their patients across southern New Jersey, U.S. This collaboration will help the company in further expansion of laboratory services.
Global Preclinical Assets Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
The sudden outbreak of COVID-19 has bought the world to a standstill. The whole world is fighting this pandemic with increased burden on hospital and healthcare professionals. However this has also opened new opportunities in the digital health platforms. The need for virtual consulting is anticipated to rise significantly during the current economic crisis.
Increasing number of inorganic strategies by the key market players during covid-19 pandemic, was expected to bolster growth of the global preclinical assets during the pandemic. For instance, in December 2021, Viroclinics-DDL, a global Contract Research Organization and CEPI, the Coalition for Epidemic Preparedness Innovations, signed an agreement which allowed Viroclinics-DDL to produce and distribute laboratory stocks of the Omicron SARS-CoV-2 variant for use in CEPI’s centralized COVID-19 vaccine testing network. The produced Omicron SARS-COV-2 variant was used for the performance of laboratory assays, assessing the neutralizing potential of COVID-19 vaccines against the new variant (Omicron).
Global Preclinical Assets Market: Key Developments
In September 2021, Viroclinics-DDL, a global contract research organization, announced the launch of Viroclinics Xellerate, a newly formed Business Unit focused on clinical trial support and global logistics services.
On February 17, 2022, Viroclinics-DDL, a global contract research organization, announced that Cerba Research, the group’s global clinical trial central and specialty laboratory services division, had merged with Viroclinics-DDL, a global specialist virology and immunology contract research organization (CRO). This merger will help the company in further expanding and transforming diagnostic solutions for clinical trials
In November 2019, Envigo RMS LLC, a global supplier of research models and associated services, announced an agreement to acquire the assets of the research models business unit of Horizon Discovery Group plc., a research company. This acquisition will help the company in further expansion of the services in clinical research.
Global Preclinical Assets Market: Restraint
One of the major restrain in the global preclinical assets market is lack of standardization as per international regulatory requirements such as:
- Study conduct
- Personnel
- Facilities
- Equipment
- Written protocols
- Operating procedures
- Study reports
- And a system of quality assurance oversight for each study to help assure the safety of FDA-regulated product
Key Players
Key players operating in the global preclinical assets market include Eurofins Scientific, ICON plc, WuXi AppTec, Viroclinics Xplore, Medpace, Inc., Charles River Laboratories., Pharmatest Services, PPD Inc., SGS SA (SGS), Intertek Group plc, Labcorp Drug Development, Laboratory Corporation of America, Inc., Crown Bioscience, Comparative Biosciences, Inc., TCG Lifesciences Private Limited., Shanghai Medicilon Inc., Domainex, Absorption Systems, AmplifyBio, and IQVIA
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Service
- Market Snapshot, By Model Type
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Technological Advancements
- Regulatory Landscape
- PEST Analysis
- Market Dynamics
- Global Preclinical Assets Market- Impact of Coronavirus (Covid-19) Pandemic
- Overall Impact
- COVID-19 Impact on the market
- Global Preclinical Assets Market, By Service, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017– 2030
- Segment Trends
- Bioanalysis and DMPK studies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- In vitro
- In-vivo
- Toxicology Testing
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- GLP
- Non-GLP
- Compound Management
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Process R&D
- Custom Synthesis
- Asymmetric Synthesis
- Others (Scale-up and cGMP)
- Safety Pharmacology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Others (Chemistry, etc.)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Global Preclinical Assets Market, By Model Type, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Patient Derived Organoid (PDO) Model
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Patient derived xenograft model
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Overview
- Global Preclinical Assets Market, By End User, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Biopharmaceutical Companies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Government Institutes
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Others (Academic and Research institutes)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Overview
- Global Preclinical Assets Market, By Region, 2017 – 2030, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profile
- Eurofins Scientific
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- ICON plc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- WuXi AppTec
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Viroclinics Xplore
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Medpace, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Charles River Laboratories.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pharmatest Services
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- PPD Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- SGS SA (SGS)
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Intertek Group plc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Labcorp Drug Development
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Laboratory Corporation of America, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Crown Bioscience
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Comparative Biosciences, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- TCG Lifesciences Private Limited.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Shanghai Medicilon Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Domainex
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Absorption Systems
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- AmplifyBio
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- IQVIA
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Eurofins Scientific
- Analyst Views
- Section
- References
- Research Methodology
- About Us
*Browse 36 market data tables and 25 figures on “Global Preclinical Assets Market” - forecast to 2030
Detailed Segmentation:
- Global Preclinical Assets Market, By Service:
-
- Bioanalysis and DMPK studies
- In vitro
- In-vivo
- Toxicology Testing
- GLP
- Non-GLP
- Compound Management
- Process R&D
- Custom Synthesis
- Asymmetric Synthesis
- Others (Scale-up, cGMP, etc.)
- Safety Pharmacology
- Others (Chemistry, etc.)
- Bioanalysis and DMPK studies
- Global Preclinical Assets Market, By Model Type:
-
- Patient Derived Organoid (PDO) Model
- Patient derived xenograft model
- Global Preclinical Assets Market, By End User:
-
- Biopharmaceutical Companies
- Government Institutes
- Others (Academic and Research institutes)
- Global Preclinical Assets Market, By Region:
- North America
- By Service
- Bioanalysis and DMPK studies
- In vitro
- In-vivo
- Toxicology Testing
- GLP
- Non-GLP
- Compound Management
- Process R&D
- Custom Synthesis
- Asymmetric Synthesis
- Others (Scale-up, cGMP, etc.)
- Safety Pharmacology
- Others (Chemistry, etc.)
- Bioanalysis and DMPK studies
- By Model Type
- Patient Derived Organoid (PDO) Model
- Patient derived xenograft model
- By End User
- Biopharmaceutical Companies
- Government Institutes
- Others (Academic and Research institutes)
- By Country
- US
- Canada
- By Service
- Latin America
- By Service
- Bioanalysis and DMPK studies
- In vitro
- In-vivo
- Toxicology Testing
- GLP
- Non-GLP
- Compound Management
- Process R&D
- Custom Synthesis
- Asymmetric Synthesis
- Others (Scale-up, cGMP, etc.)
- Safety Pharmacology
- Others (Chemistry, etc.)
- Bioanalysis and DMPK studies
- By Model Type
- Patient Derived Organoid (PDO) Model
- Patient derived xenograft model
- By End User
- Biopharmaceutical Companies
- Government Institutes
- Others (Academic and Research institutes)
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Service
- Europe
- By Service
- Bioanalysis and DMPK studies
- In vitro
- In-vivo
- Toxicology Testing
- GLP
- Non-GLP
- Compound Management
- Process R&D
- Custom Synthesis
- Asymmetric Synthesis
- Others (Scale-up, cGMP, etc.)
- Safety Pharmacology
- Others (Chemistry, etc.)
- Bioanalysis and DMPK studies
- By Model Type
- Patient Derived Organoid (PDO) Model
- Patient derived xenograft model
- By End User
- Biopharmaceutical Companies
- Government Institutes
- Others (Academic and Research institutes)
- By Country
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Service
- Asia Pacific
- By Service
- Bioanalysis and DMPK studies
- In vitro
- In-vivo
- Toxicology Testing
- GLP
- Non-GLP
- Compound Management
- Process R&D
- Custom Synthesis
- Asymmetric Synthesis
- Others (Scale-up, cGMP, etc.)
- Safety Pharmacology
- Others (Chemistry, etc.)
- Bioanalysis and DMPK studies
- By Model Type
- Patient Derived Organoid (PDO) Model
- Patient derived xenograft model
- By End User
- Biopharmaceutical Companies
- Government Institutes
- Others (Academic and Research institutes)
- By Country
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Service
- Middle East
- By Service
- Bioanalysis and DMPK studies
- In vitro
- In-vivo
- Toxicology Testing
- GLP
- Non-GLP
- Compound Management
- Process R&D
- Custom Synthesis
- Asymmetric Synthesis
- Others (Scale-up, cGMP, etc.)
- Safety Pharmacology
- Others (Chemistry, etc.)
- Bioanalysis and DMPK studies
- By Model Type
- Patient Derived Organoid (PDO) Model
- Patient derived xenograft model
- By End User
- Biopharmaceutical Companies
- Government Institutes
- Others (Academic and Research institutes)
- By Country
- GCC
- Israel
- Rest of Middle East
- By Service
- Africa
- By Service
- Bioanalysis and DMPK studies
- In vitro
- In-vivo
- Toxicology Testing
- GLP
- Non-GLP
- Compound Management
- Process R&D
- Custom Synthesis
- Asymmetric Synthesis
- Others (Scale-up, cGMP, etc.)
- Safety Pharmacology
- Others (Chemistry, etc.)
- Bioanalysis and DMPK studies
- By Model Type
- Patient Derived Organoid (PDO) Model
- Patient derived xenograft model
- By End User
- Biopharmaceutical Companies
- Government Institutes
- Others (Academic and Research institutes)
- By Country/Region
- South Africa
- Central Africa
- North Africa
- By Service
- North America